Fintel reports that on November 14, 2025, HC Wainwright & Co. maintained coverage of Cytosorbents (NasdaqCM:CTSO) with a Neutral recommendation. Analyst Price Forecast Suggests 672.73% Upside As of ...
Fintel reports that on December 16, 2025, D. Boral Capital maintained coverage of Cytosorbents (NasdaqCM:CTSO) with a Buy recommendation. Analyst Price Forecast Suggests 736.72% Upside As of December ...
StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research report released on Wednesday. The brokerage issued a hold rating on the medical research company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results